Highlights
1 patent
About
Steroid Substitutes Based on Synthetic Cannabinoid Acids
EPM develops prescription medicine derived from synthetic cannabinoid acids to address unmet patient needs.
The company has created a pipeline that includes the discovery of 14 protected synthetic molecules, including eight novel structures and production process intellectual property.
Currently, EPM's focus is on two main therapeutic conditions: metabolic disorders (Prader-Willi syndrome) and inflammatory skin disease (psoriasis).
Identity
| Name | EPM |
|---|---|
| Slug | epm |
| Former names | EUROPACIFIC MEDICAL |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkPTir58LDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Bnei Brak |
| HQ address | Kinneret St 5, Bnei Brak, Israel |
Web & social
| Website | https://epmip.com/ |
|---|---|
| Careers page | https://epmip.com/careers |
| https://www.linkedin.com/company/54275941 | |
| Twitter / X | https://twitter.com/EPMIP |
| https://www.facebook.com/EPMIP | |
| YouTube | https://www.youtube.com/channel/UCr8mb7WyEcxGCEXIyYS0Cog |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsHerbalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
oral-drugsdrug-developmentmedical-cannabiscannabisrespiratorydrug-discoverygeneric-drugspharmaceuticalsinflammatory-diseasesmetabolic-disease
Funding
| Total raised | $2.5M |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}